Fudan-Zhangjiang Bio-Pharmaceutical Subscribes to RMB150 Million Structured Deposit Product from Bank of China

Stock News

Yesterday

Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (01349) has announced that it recently entered into a structured deposit product agreement with Bank of China, agreeing to subscribe to a structured deposit product in the amount of RMB150 million using temporarily idle raised funds from its A-share public offering.

The subscription was made by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (688505) to Bank Of China Limited (601988), utilizing proceeds from the company's A-share initial public offering that are currently idle.

FUDANZHANGJIANG (01349) stated in its filing that the agreement with BANK OF CHINA (03988) covers a structured deposit product valued at RMB150 million, funded entirely by temporarily unused proceeds from the company's A-share offering.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1152704278"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152704278\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152704278?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-09 17:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152704278","market":"other","top_or_hot":-1,"title":"Fudan-Zhangjiang Bio-Pharmaceutical Subscribes to RMB150 Million Structured Deposit Product from Bank of China","media":"Stock News","content":"<p>Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (01349) has announced that it recently entered into a structured deposit product agreement with Bank of China, agreeing to subscribe to a structured deposit product in the amount of RMB150 million using temporarily idle raised funds from its A-share public offering.<br><br>The subscription was made by <b>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.</b> (<b>688505</b>) to <b>Bank Of China Limited</b> (<b>601988</b>), utilizing proceeds from the company's A-share initial public offering that are currently idle.<br><br><b>FUDANZHANGJIANG</b> (<b>01349</b>) stated in its filing that the agreement with <b>BANK OF CHINA</b> (<b>03988</b>) covers a structured deposit product valued at RMB150 million, funded entirely by temporarily unused proceeds from the company's A-share offering.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fudan-Zhangjiang Bio-Pharmaceutical Subscribes to RMB150 Million Structured Deposit Product from Bank of China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFudan-Zhangjiang Bio-Pharmaceutical Subscribes to RMB150 Million Structured Deposit Product from Bank of China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-10-09 17:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (01349) has announced that it recently entered into a structured deposit product agreement with Bank of China, agreeing to subscribe to a structured deposit product in the amount of RMB150 million using temporarily idle raised funds from its A-share public offering.<br><br>The subscription was made by <b>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.</b> (<b>688505</b>) to <b>Bank Of China Limited</b> (<b>601988</b>), utilizing proceeds from the company's A-share initial public offering that are currently idle.<br><br><b>FUDANZHANGJIANG</b> (<b>01349</b>) stated in its filing that the agreement with <b>BANK OF CHINA</b> (<b>03988</b>) covers a structured deposit product valued at RMB150 million, funded entirely by temporarily unused proceeds from the company's A-share offering.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2097828557.USD","symbol_name":"AZ EQUITY CHINA \"A\" (USD) ACC","start_time":0,"source_url":"","article_id":"1152704278","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152704278","pubTimestamp":1791537162,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (01349) has announced that it recently entered into a structured deposit product agreement with Bank of China, agreeing to subscribe to a structured...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601988":"中国银行","688505":"复旦张江","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","IE00BQJZWZ67.USD":"FRANKLIN MV ASIA PACIFIC EX JAPAN EQUITY GROWTH AND INCOME \"A\" (USD) INC (M) PLUS","SG9999001093.SGD":"United Greater China Fund A Acc SGD","BK0278":"货币金融","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK0239":"医药制造","BK1231":"综合性银行","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","BK1521":"挪威政府全球养老基金持仓","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","HK0000286598.CNH":"中银保诚中国价值基金 A","03143":"华夏香港银行股","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1497733631.SGD":"Eastspring Investments - Asian Low Volatility Equity Fund ASDM SGD","03988":"中国银行","LU0651947912.USD":"BGF EMERGING MARKETS EQUITY INCOME \"A5G\" (USD) INC","LU0211977185.USD":"EASTSPRING INVESTMENTS GREATER CHINA EQUITY \"A\" ACC","LU1282651121.HKD":"ALLIANZ GEM EQUITY HIGH DIVIDEND \"AMG\" (HKD) INC","BK0183":"MSCI概念","LU1224444064.USD":"ALLIANZ GEM EQUITY HIGH DIVIDEND \"AM\" (USDHDG) INC","BK0188":"融资融券","BK0012":"证金概念","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK0015":"沪股通50","IE00B19Z5X02.USD":"Legg Mason QS - MV Asia Pacific ex Japan Equity Growth and Income A Acc USD","LU1634259557.SGD":"Eastspring Investments - Asian Low Volatility Equity Fund AS SGD-H","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","BK0028":"国家队","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU1051769294.HKD":"BGF EMERGING MARKETS EQUITY INCOME \"A6\"(HKDHDG) INC","LU0293314216.USD":"ALLIANZ GEM EQUITY HIGH DIVIDEND \"A\" (USD) ACC","LU0651946864.USD":"贝莱德新兴市场股票收益A2","01349":"复旦张江","LU1522347837.USD":"EASTSPRING INV ASIAN LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC A","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","BK1191":"制药","LU1048588211.SGD":"Blackrock Asian Dragon A2 SGD-H","BK1560":"内银股","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","LU1515016050.SGD":"Blackrock Emerging Markets Equity Income A6 SGD-H","LU1051768304.USD":"贝莱德新兴市场股票收益A6","LU1282651048.USD":"ALLIANZ GEM EQUITY HIGH DIVIDEND \"AMG\" (USD) INC","LU1634259391.SGD":"Eastspring Investments - Asian Low Volatility Equity Fund AS SGD","LU1497734951.SGD":"Eastspring Investments - Asian Low Volatility Equity Fund ASDM SGD-H","LU0072462343.USD":"贝莱德亚洲巨龙基金","LU0348805143.USD":"ALLIANZ ENHANCED ALL CHINA EQUITY \"A\" (USD) INC","SG9999006597.SGD":"United China-India Dynamic Growth SGD","LU1497733557.USD":"EASTSPRING INV ASIAN LOW VOLATILITY EQUITY FUND \"A\" (USD) INC A","IE00BWDBJ730.SGD":"Legg Mason QS - MV Asia Pacific ex Japan Equity Growth and Income A Mdis SGD-H Plus"},"translate_title":"复旦张江生物医药认购中国银行人民币1.5亿元结构性存款产品","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601988":1,"688505":1,"03988":1,"01349":1,"03143":1},"content_text":"Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (01349) has announced that it recently entered into a structured deposit product agreement with Bank of China, agreeing to subscribe to a structured deposit product in the amount of RMB150 million using temporarily idle raised funds from its A-share public offering.The subscription was made by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (688505) to Bank Of China Limited (601988), utilizing proceeds from the company's A-share initial public offering that are currently idle.FUDANZHANGJIANG (01349) stated in its filing that the agreement with BANK OF CHINA (03988) covers a structured deposit product valued at RMB150 million, funded entirely by temporarily unused proceeds from the company's A-share offering.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}